Prenatal Screening Unit, Department of Clinical Biochemistry, King George Hospital, Barley Lane, Goodmayes, Essex, UK.
Prenat Diagn. 2012 Jul;32(7):644-8. doi: 10.1002/pd.3875.
To investigate the levels of tumour markers CA 19-9 and CA 15-3 in the first trimester maternal serum of euploid control and trisomy 21 pregnancies.
Maternal serum marker levels of 69 trisomy 21 and 388 euploid controls were quantified by the Kryptor analyser, and levels were compared between the two groups after analysis for confounding factors. Monte Carlo simulation was carried out to determine the effect of adding potential markers to the combined test.
Neither marker was affected by gestational age; however, CA 19-9 required correction for maternal weight. CA 19-9 was significantly increased in trisomy 21 pregnancies (0.98 MoM in euploid, 1.16 MoM in trisomy 21, p = 0.024). Levels of CA 15-3 were not found to differ significantly (1.03 MoM in euploid, 1.09 in trisomy 21, p = 0.130). Detection rates were unaffected by addition of CA 19-9 to the combined test.
Although a small significant increase in CA 19-9 levels was found in trisomy 21 group, it is unlikely to be of any use as part of a trisomy 21 screening tool.
研究唐氏综合征患儿和正常二倍体妊娠孕妇孕早期母血清肿瘤标志物 CA19-9 和 CA15-3 的水平。
通过 Kryptor 分析仪对 69 例唐氏综合征患儿和 388 例正常二倍体孕妇的母血清标志物水平进行定量分析，对混杂因素进行分析后比较两组之间的水平。通过蒙特卡罗模拟确定将潜在标志物添加到联合检测中的效果。
两种标志物均不受孕龄影响，但 CA19-9 需要校正母亲体重。唐氏综合征组的 CA19-9 明显升高（正常二倍体组为 0.98MoM，唐氏综合征组为 1.16MoM，p=0.024）。CA15-3 水平无明显差异（正常二倍体组为 1.03MoM，唐氏综合征组为 1.09MoM，p=0.130）。添加 CA19-9 对联合检测的检出率无影响。
尽管唐氏综合征组 CA19-9 水平略有升高，但作为唐氏综合征筛查工具的一部分，其作用可能不大。
